Targeting US$610 billion longevity market, biotech firms race to reverse ageing
Biotech firms are increasingly leveraging AI to target the burgeoning US$610 billion longevity market, aiming to reverse or slow the aging process. Companies like METiS TechBio are using AI algorithms for drug delivery to specific cells, while others focus on reprogramming cells to combat age-related decline. The United States leads this field, fueled by substantial private investment, with global investment in longevity reaching US$8.49 billion. AI
IMPACT AI integration in biotech is accelerating the development of anti-aging therapies and personalized health predictions.